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Abstract: OBJECTIVES The aim of this study was to evaluate clinical outcomes of unprotected left
main coronary artery percutaneous coronary intervention (PCI) with new-generation drug-eluting stents
in a ”real world” population. BACKGROUND PCI of the unprotected left main coronary artery is
currently recommended as an alternative to coronary artery bypass grafting (CABG) in selected patients.
METHODS All consecutive patients with unprotected left main coronary artery stenosis treated by PCI
with second-generation drug-eluting stents were analyzed in this international, all-comers, multicenter
registry. The results were compared with those from the historical DELTA 1 (Drug Eluting Stent for Left
Main Coronary Artery) CABG cohort using propensity score stratification. The primary endpoint was
the composite of death, myocardial infarction (MI), or stroke at the median time of follow-up. RESULTS
A total of 3,986 patients were included. The mean age was 69.6 ± 10.9 years, diabetes was present
in 30.8%, and 21% of the patients presented with acute MI. The distal left main coronary artery was
involved in 84.6% of the lesions. At a median of 501 days (฀17 months) of follow-up, the occurrence of
the primary endpoint of death, MI, or cerebrovascular accident was lower in the PCI DELTA 2 group
compared with the historical DELTA 1 CABG cohort (10.3% vs. 11.6%; adjusted hazard ratio: 0.73;
95% confidence interval: 0.55 to 0.98; p = 0.03). Of note, an advantage of PCI was observed with respect
to cerebrovascular accident (0.8% vs. 2.0%; adjusted hazard ratio: 0.37; 95% confidence interval: 0.16 to
0.86; p = 0.02), while an advantage of CABG was observed with respect to target vessel revascularization
(14.2% vs. 2.9%; adjusted hazard ratio: 3.32; 95% confidence interval: 2.12 to 5.18; p < 0.0001).
CONCLUSIONS After a median follow-up period of 17 months, PCI with new-generation drug-eluting
stents was associated with an overall low rate of the composite endpoint of death, MI, or cerebrovascular
accident.
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ABSTRACT
OBJECTIVES The aim of this study was to evaluate clinical outcomes of unprotected left main coronary artery
percutaneous coronary intervention (PCI) with new-generation drug-eluting stents in a “real world” population.
BACKGROUND PCI of the unprotected left main coronary artery is currently recommended as an alternative to
coronary artery bypass grafting (CABG) in selected patients.
METHODS All consecutive patients with unprotected left main coronary artery stenosis treated by PCI with
second-generation drug-eluting stents were analyzed in this international, all-comers, multicenter registry. The results
were compared with those from the historical DELTA 1 (Drug Eluting Stent for Left Main Coronary Artery) CABG
cohort using propensity score stratification. The primary endpoint was the composite of death, myocardial infarction (MI),
or stroke at the median time of follow-up.
RESULTS A total of 3,986 patients were included. The mean age was 69.6  10.9 years, diabetes was present in 30.8%,
and 21% of the patients presented with acute MI. The distal left main coronary artery was involved in 84.6% of the
lesions. At a median of 501 days (z17 months) of follow-up, the occurrence of the primary endpoint of death, MI,
or cerebrovascular accident was lower in the PCI DELTA 2 group compared with the historical DELTA 1 CABG cohort
(10.3% vs. 11.6%; adjusted hazard ratio: 0.73; 95% confidence interval: 0.55 to 0.98; p ¼ 0.03). Of note, an advantage
of PCI was observed with respect to cerebrovascular accident (0.8% vs. 2.0%; adjusted hazard ratio: 0.37;
95% confidence interval: 0.16 to 0.86; p ¼ 0.02), while an advantage of CABG was observed with respect to target
vessel revascularization (14.2% vs. 2.9%; adjusted hazard ratio: 3.32; 95% confidence interval: 2.12 to 5.18; p < 0.0001).
CONCLUSIONS After a median follow-up period of 17 months, PCI with new-generation drug-eluting stents
was associated with an overall low rate of the composite endpoint of death, MI, or cerebrovascular accident.
(J Am Coll Cardiol Intv 2017;10:2401–10) © 2017 by the American College of Cardiology Foundation.
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P
ercutaneous treatment of unpro-
tected left main coronary artery
(ULMCA) disease evolved over time
and currently is accepted as an alternative
to coronary artery bypass grafting (CABG)
in selected patients (1). In this challenging
subset of patients, percutaneous coronary
intervention (PCI) with drug-eluting stents
(DES) has been demonstrated to be feasible
and safe at midterm clinical follow-up (2–21).
The noninferiority of PCI compared with
CABG in terms of major adverse cardiac and
cerebrovascular events (MACCE) in patients
with ULMCA disease was reported in the
randomized SYNTAX (Synergy Between PCI
With Taxus and Cardiac Surgery) trial in the era
of first-generation DES (22,23). Recently, the
EXCEL (Evaluation of XIENCE Versus Coro-
nary Artery Bypass Surgery for Effectiveness of
Left Main Revascularization) trial demonstrated the
noninferiority of PCI with second-generation DES
versus CABG in patients with ULMCA disease and in-
termediate to low SYNTAX scores with respect to death,
cerebrovascular accident (CVA), or myocardial infarc-
tion (MI) at 3 years (24). Conversely, higher rates of the
primary endpoint of death, CVA, MI, or any repeat
coronary revascularization with PCI were reported in
the NOBLE (Nordic-Baltic-British Left Main Revascu-
larization Study) trial at 5 years of follow-up (25).
Patterns of use and clinical outcomes of PCI with
new-generation DES in real-world practice remain
unclear. Therefore, the aim of the present study was to
evaluate clinical outcomes of ULMCA PCI with second-
generation DES in a “real world” setting and compare
these with CABG from the historical DELTA 1 (Drug
Eluting Stent for Left Main Coronary Artery) registry (2).
METHODS
The DELTA 2 registry included “all comers” patients
with ULMCA disease treated with PCI and
new-generation DES between March 2006 and
December 2015 at 19 centers in 7 countries.
New-generation DES included in the registry were
the following: everolimus-eluting stents (XIENCE,
Abbott Vascular, Santa Clara, California; PROMUS,
Boston Scientific, Natick, Massachusetts; and
SYNERGY Boston Scientific), zotarolimus-eluting
stents [Endeavor, Resolute Integrity, and Resolute
Onyx, Medtronic, Santa Rosa, California), biolimus-
eluting stents (Nobori, Terumo, Tokyo, Japan; and
BioMatrix, Biosensors, Newport Beach, California),
and sirolimus-eluting stents (Ultimaster, Terumo; and
Orsiro, Biotronik, Bülach, Switzerland).
At all institutions, patients were evaluated by both
interventional cardiologists and cardiac surgeons,
and the decision to perform PCI or CABG was made as
in the DELTA 1 registry on the basis of: 1) hemody-
namic conditions; 2) lesion characteristics; 3) vessel
size; 4) the presence of comorbidities; 5) quality of
arterial and/or venous conduits for grafting; and 6)
patient and/or referring physician preferences.
In all cases, the selected revascularization approach
seemed suitable to guarantee complete revasculari-
zation (2). All data related to hospital admissions,
procedures, and outcomes were collected at each
center within the hospital recording network.
Information on clinical status at the latest
clinical follow-up was collected by clinical visits,
telephone interviews, and referring physicians.
Dual-antiplatelet therapy was administered according
to hospital and physician practice. Angiographic
follow-up was scheduled according to hospital
practice or if a noninvasive evaluation or clinical
presentation suggested ischemia.
DEFINITIONS. Study definitions of the DELTA 2
registry were consistent with the previously published
DELTA 1 registry (2). The following events were
analyzed cumulatively at the latest clinical follow-up
available: all-cause and cardiac death, MI, CVA,
target lesion revascularization (TLR), and target vessel
revascularization (TVR). The occurrence of stent
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thrombosis was defined on the basis of the Academic
Research Consortium criteria (26).
Diagnostic angiograms were scored according to
the SYNTAX score algorithm at the site laboratory
according to hospital practice (27). A true bifurcation
was defined as a Medina classification of 1.1.1, 0.1.1,
or 1.1.0.
STUDY ENDPOINTS. The study endpoints used in
the DELTA 2 registry were consistent with those
in the DELTA 1 registry (2). The primary composite
study endpoint was the incidence of all-cause
death, MI, or CVA at median time of follow-up.
The secondary endpoints were the occurrence of
death, death or MI, MACCE, TLR, and TVR.
COMPARISON WITH THE HISTORICAL DELTA 1 CABG
COHORT. The DELTA 1 registry was a multicenter
registry evaluating PCI versus CABG for left main
coronary artery treatment (2). The study population
included consecutive all-comers patients with ULMCA
stenosis treated with PCI and “first-generation” DES
implantation or CABG between April 2002 and April
2006 at 14 centers worldwide. The surgical cohort of
the DELTA 1 population was used in this study as a
historical surgical group and compared with the
DELTA 2 (28,29). The DELTA 2 registry did not include
a parallel contemporary CABG group.
STATISTICAL ANALYSIS. Individual patient data
were pooled in a single pre-specified structured
dataset and analyzed. Baseline characteristics are
reported as number (percentage), mean  SD, or
median (interquartile range). Event rates with
95% confidence intervals (CI) and absolute rate
differences at follow-up were estimated using the
Kaplan-Meier method as time to first event. Predictors
for endpoint events were estimated using multivar-
iate Cox regression analysis including all variables
with p values <0.10 in univariate analysis and using a
rule of 1:10 covariates per number of events to avoid
overfitting. To account for pre-treatment difference
between the DELTA 2 cohort and the historical DELTA
1 CABG cohort, a propensity score was generated by
means of a logistic regression model. Calibration of
the logistic regression model was assessed using the
Hosmer-Lemeshow test. The following covariates
were included in the logistic regression model to
generate the propensity score: age, male sex, diabetes,
smoking history, family history of coronary artery
disease, acute MI (ST-segment elevation MI or non–
ST-segment elevation MI), previous CABG, previous
PCI, and right coronary artery disease. Subsequently,
Cox regression models stratified by quintiles of pro-
pensity score were performed to estimate adjusted
differences between treatments (PCI vs. CABG).
To account for intercenter heterogeneity, center
identifiers were included as a covariate within the Cox
regression models. The proportionality assumption
of the Cox regression models was tested using
the Schoenfeld residual method. Multicollinearity
across covariates in the multivariate model was
assessed using the variance inflation factor, with
values >10 indicating significant multicollinearity.
A p value <0.05 was considered to indicate statistical
significance. Analyses were performed using Stata
version 14.0 (StataCorp, College Station, Texas) and
SPSS version 21.0 (SPSS, Chicago, Illinois).
RESULTS
The baseline clinical characteristics of the study
population are summarized in Table 1. A total of
3,986 patients were included. The mean age was
69.6  10.9 years, diabetes was present in 30.8%,
and chronic kidney disease was present in 31.2%.
Of note, 14.8% of the patients presented with non–
ST-segment elevation MI and 6.2% with ST-segment
elevation MI.
TABLE 1 Baseline Clinical Characteristics (n ¼ 3,986)
Age, yrs 69.6  10.9
Male 2,969 (74.5)




Insulin dependent diabetes 300 (7.6)
Smoking history (current and former) 1,423 (35.7)
Family history of CAD 1,059 (28.7)
Chronic kidney disease 1,199 (31.2)
Previous MI 1,115 (28.2)
Previous CABG 329 (8.3)
Previous PCI 1,639 (41.5)
LVEF, % 53.4  11.3
EuroSCORE 1 3.7 (1.8–6.9)*
EuroSCORE 2 1.3 (0.9–2.8)*
Clinical presentation
Stable angina/silent ischemia 2,546 (63.9)
Unstable angina 604 (15.2)
NSTEMI 588 (14.8)
STEMI 248 (6.2)
Values are mean  SD, n (%), or median (interquartile range), calculated
with available sample data. *EuroSCORE 1 was available in 1,100 patients and
EuroSCORE 2 in 868 patients.
CABG ¼ coronary artery bypass grafting; CAD ¼ coronary artery disease;
EuroSCORE ¼ European System for Cardiac Operative Risk Evaluation; LVEF ¼ left
ventricular ejection fraction;MI¼myocardial infarction;NSTEMI¼non–ST-segment
elevation myocardial infarction; PCI ¼ percutaneous coronary intervention;
STEMI ¼ ST-segment elevation myocardial infarction.
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Angiographic and procedural characteristics are
illustrated in Table 2. The distal left main coronary
artery was involved in 84.6% of the lesions. The
prevalence of urgent or emergent procedures was
28.2%, and a radial approach was chosen in 39.3%
of the procedures. A total of 2,986 patients (74.9%)
received everolimus-eluting stents, 364 (9.1%)
zotarolimus-eluting stents, 521 (13.1%) biolimus-
eluting stents, and 115 (2.9%) sirolimus-eluting
stents. Intravascular ultrasound was used in 36.1%
of the cases. In the majority of the cases, a
provisional approach was used; double-stenting
was performed in only 753 patients (20.4%). When
a 2-stent approach was chosen, final kissing
balloon inflation was used in most of the cases
(83.9%).
HOSPITAL AND FOLLOW-UP CLINICAL OUTCOMES.
In-hospital death occurred in 53 patients (1.3%), and
the rate was significantly lower in elective cases
(elective vs. urgent or emergent, 0.5% vs. 3.6%;
p < 0.001). Death was considered of cardiac origin in
43 patients (1.1%). Periprocedural MI occurred in 158
patients (4.0%), and in-hospital CVA occurred in
7 (0.2%). In-hospital TVR was performed in 15 (0.4%)
and TLR in 10 (0.3%) patients.
During follow-up (median 501 days; interquartile
range: 318 to 1,002 days; clinical follow-up rate
88.1%), all-cause death occurred in 329 patients
(8.3%). Among them, 210 (5.3%) were adjudicated as
cardiac deaths. TVR was performed in 515 patients
(12.9%) and TLR in 311 patients (7.8%). Definite stent
thrombosis occurred in 28 patients (0.7%), of which
6 were acute, 5 subacute, 13 late, and 4 very late.
Probable stent thrombosis occurred in 23 patients
(0.6%). In-hospital and follow-up MACCE are
illustrated in Table 3. Kaplan-Meier curves for the
primary endpoint of death, MI, or CVA, death, death
or MI, and MACCE are illustrated in Figure 1.
MULTIVARIATE ANALYSIS FOR PREDICTORS OF
PRIMARY AND SECONDARY ENDPOINTS. On Cox
regression multivariate analysis, age (HR: 1.03; 95%
CI: 1.01 to 1.02; p ¼ 0.003), dyslipidemia (HR: 0.70;
95% CI: 0.51 to 0.96; p ¼ 0.02), diabetes (HR: 1.51; 95%
CI: 1.12 to 2.02; p ¼ 0.006), chronic kidney disease
TABLE 2 Lesion and Procedural Characteristics (n ¼ 3,986)
Multivessel disease 2,962 (74.3)
LAD/LCx disease 3,497 (87.7)
RCA disease 1,925 (48.3)
SYNTAX score 27.0  10.6*
Lesion location
Ostial/shaft only 614 (15.4)
Involving distal bifurcation 3,372 (84.6)




Radial access 1,568 (39.3)
Number of vessels treated 1.6  0.7
Number of lesions treated 1.9  1.0
Intravascular ultrasound 1,437 (36.1)




Everolimus-eluting stent 2,986 (74.9)
Zotarolimus-eluting stent 364 (9.1)
Biolimus-eluting stent 521 (13.1)
Sirolimus-eluting stent 115 (2.9)
Left main coronary artery stent diameter, mm 3.59  0.37








Maximum balloon diameter, mm 4.0  0.5
Maximum pressure, atm 18.5  4.7
Kissing balloon inflation 1,780 (48.2)
Values are n (%) or mean  SD, calculated with available sample data. *SYNTAX
score was available in 2,132 patients.
LAD ¼ left anterior descending coronary artery; LCx ¼ left circumflex coronary
artery; RCA ¼ right coronary artery; SYNTAX ¼ Synergy Between Percutaneous
Coronary Intervention With Taxus and Cardiac Surgery.
TABLE 3 Major Adverse Cardiac and Cerebrovascular Events
in Hospital and During Clinical Follow-Up (n ¼ 3,986)
In-hospital events
Cardiac death 43 (1.1)
Noncardiac death 10 (0.3)
Myocardial infarction 158 (4.0)
Target lesion revascularization 10 (0.3)
Target vessel revascularization 15 (0.4)
Cerebrovascular event 7 (0.2)
MACCE 211 (5.3)
Follow-up events
Cardiac death 210 (5.3)
Noncardiac death 119 (3.0)
Myocardial infarction 92 (2.3)
Target lesion revascularization 311 (7.8)
Target vessel revascularization 515 (12.9)
Cerebrovascular event 32 (0.8)
MACCE 846 (21.2)
Values are n (%). Numbers of events during follow-up are cumulatively counted at
latest clinical follow-up.
MACCE ¼ major adverse cardiac and cerebrovascular event(s).
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(HR: 1.58; 95% CI: 1.16 to 2.15; p ¼ 0.004), left
ventricular ejection fraction (HR: 0.96; 95% CI: 0.95
to 0.97; p < 0.001), emergent or urgent procedure
(HR: 1.83; 95% CI: 1.33 to 2.52; p < 0.001), femoral
access (HR: 1.68; 95% CI: 1.17 to 2.42; p ¼ 0.005), and
requirement for Rotablator (HR: 1.73; 95% CI: 1.02 to
2.94; p ¼ 0.04) were found to be predictors of the
composite primary endpoint of death, MI, and CVA
(Online Table 1).
Predictors of MACCE were diabetes (HR: 1.72; 95%
CI: 1.43 to 2.07; p < 0.001), left ventricular ejection
fraction (HR: 0.98; 95% CI: 0.97 to 0.99), multivessel
disease (HR: 1.35; 95% CI: 1.00 to 1.82; p ¼ 0.049),
emergent or urgent procedure (HR: 1.34; 95% CI: 1.07
to 1.67; p ¼ 0.01), femoral access (HR: 1.27; 95% CI:
1.02 to 1.58; p ¼ 0.03), requirement for intra-aortic
balloon pump (HR: 1.78; 95% CI: 1.33 to 2.38;
p < 0.001), pre-dilation (HR: 0.82; 95% CI: 0.67 to
0.99; p ¼ 0.04), requirement for Rotablator (HR: 1.87;
95% CI: 1.34 to 2.60; p < 0.001), left main coronary
artery stent diameter (HR: 0.70; 95% CI: 0.53 to 0.92;
p ¼ 0.01), and performance of bifurcation double-
stenting (HR: 1.37; 95% CI: 1.09 to 1.72; p ¼ 0.007)
(Online Table 2).
Predictors of TVR were age (HR: 0.98; 95% CI: 0.97
to 0.99; p ¼ 0.001), diabetes (HR: 1.84; 95% CI: 1.48
to 2.29; p < 0.001), requirement for Rotablator (HR:
1.90; 95% CI: 1.26 to 2.87; p ¼ 0.002), left main
coronary artery stent diameter (HR: 0.57; 95% CI: 0.41
to 0.79; p ¼ 0.001), and performance of bifurcation
FIGURE 1 Time-to-Event Curves for Death, MI, or CVA; Death or MI; Death; and MACCE in the Overall Population
CVA ¼ cerebrovascular accident; MACCE ¼ major adverse cardiac and cerebrovascular event(s); MI ¼ myocardial infarction.
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double-stenting (HR: 1.50; 95% CI: 1.13 to 1.97;
p ¼ 0.004) (Online Table 3).
COMPARISON BETWEEN DELTA 2 AND HISTORICAL
DELTA 1 CABG PATIENTS. Baseline differences be-
tween DELTA 2 PCI (n ¼ 3,986) and historical DELTA 1
CABG (n ¼ 901) patients are summarized in Online
Table 4. Patients in the DELTA 2 cohort were older;
were more frequently male; more frequently had
hypertension, dyslipidemia, and histories of CABG and
PCI; and more often presented with non–ST-segment
elevation MI or ST-segment elevation MI.
Considering the difference in follow-up duration
(median 501 days in DELTA 2 and 1,524 days in
DELTA 1 CABG), all endpoints were compared at
501 days of follow-up. The propensity score model
was well calibrated (goodness-of-fit test, p ¼ 0.12).
Unadjusted and adjusted outcomes between the
DELTA 2 PCI and historical DELTA 1 CABG cohorts are
illustrated in Table 4 and Figures 2A and 2B. The risk
for the primary endpoint of death, MI, and CVA was
lower in the PCI group. In particular, PCI was associ-
ated with lower risk for cerebrovascular events.
Conversely, an advantage of CABG was observed
with respect to repeated coronary revascularization.
Indeed, no significant difference was observed in
MACCE.
DISCUSSION
The main findings of this large, all-comers interna-
tional registry study evaluating all consecutive PCI
procedures with new-generation DES in ULMCA le-
sions are as follows. 1) At a median time of follow-up
of 501 days, the primary endpoint (death, MI, or CVA)
occurred in 416 (10.4%) patients. Cumulative all-
cause mortality was 8.3%. MI was observed in 92
(2.3%) and CVA in 32 (0.8%) patients. 2) The second-
ary endpoint of MACCE occurred in 846 patients
(21.2%), driven mostly by TVR (12.9%) and TLR
(7.8%). 3) At a median time of follow-up of 501 days,
the occurrence of the primary endpoint of death,
MI, or CVA was lower in the PCI DELTA 2 cohort
compared with the historical DELTA 1 CABG cohort.
In particular, PCI was associated with lower risk for
cerebrovascular events. Conversely, an advantage
of CABG was observed with respect to repeated
coronary revascularization. Indeed, no difference was
observed in MACCE.
Current guidelines recommend PCI as an alterna-
tive to CABG in selected patients (1). In this chal-
lenging subset of patients, PCI with DES implantation
has been shown in several registries to be a feasible
and safe approach at mid- and long-term follow-up
(2–21).
The study population included in DELTA 2 is a
real-world population including patients usually
excluded from randomized clinical trials. Chronic
kidney disease was present in 31.2% of the patients,
and the clinical presentation was non–ST-segment
elevation MI in 14.8% and ST-segment elevation MI in
6.2% of the patients. Moreover, urgent or emergent
procedures were performed in 28.2% of the
patients, and the Rotablator was required in 6.1%.
Furthermore, the majority of patients (74.3%) had
multivessel disease, distal left main coronary artery
bifurcation disease was present in 84.6%, and the
mean SYNTAX score was 27.0  10.6. Despite a high
clinical and lesion risk profile, the primary endpoint
occurred in only 416 patients (10.4%). Femoral access
was found in our registry to be an independent
predictor of the primary endpoint, in alignment with
current research (30–32). Clearly we cannot exclude










(95% CI) p Value†
Death, MI, or CVA 312 (10.3 [9.2 to 11.5]) 101 (11.6 [9.6 to 13.9]) 1.3 (2.4 to 0.4) 0.82 (0.66 to 1.03) 0.73 (0.55 to 0.98) 0.03
Death 240 (7.8 [6.9 to 8.9]) 68 (7.9 [6.3 to 9.9]) 0.1 (1.0 to 0.6) 0.96 (0.73 to 1.26) 0.78 (0.56 to 1.09) 0.15
MI 79 (2.8 [2.3 to 3.5]) 25 (2.9 [2.0 to 4.3]) 0.6 (0.8 to 0.3) 0.87 (0.56 to 1.37) 0.89 (0.49 to 1.63) 0.71
CVA 22 (0.8 [0.5 to 1.2]) 17 (2.0 [1.3 to 3.2]) 1.2 (2.0 to 0.8) 0.33 (0.18 to 0.63) 0.37 (0.16 to 0.86) 0.02
Death or MI 300 (9.9 [8.9 to 11.0]) 89 (10.3 [8.4 to 12.5]) 0.4 (1.5 to 0.5) 0.91 (0.72 to 1.15) 0.77 (0.57 to 1.04) 0.09
TVR 402 (14.2 [12.9 to 15.6]) 23 (2.9 [1.9 to 4.3]) 11.3 (11.0 to 11.3) 5.11 (3.35 to 7.77) 3.32 (2.12 to 5.18) <0.0001
TLR 241 (8.5 [7.5 to 9.6]) 21 (2.6 [1.7 to 4.0]) 5.9 (5.6 to 5.9) 3.23 (2.07 to 5.05) 2.39 (1.45 to 3.94) 0.001
Definite/probable ST 49 (1.6 [1.2 to 2.1]) — — — — —
MACCE 652 (21.6 [20.2 to 23.2]) 120 (13.9 [11.7 to 16.3]) 7.7 (6.9 to 8.5) 1.64 (1.48 to 1.82) 1.16 (0.92 to 1.46) 0.20
Values are n (% [95% CI]) or hazard ratio (95% CI). All endpoints were evaluated at 501 days of follow-up. *Adjusted hazard ratios generated with Cox models including center identifiers as a covariate and
stratified by quintiles of propensity score. †Adjusted p value.
ARD ¼ absolute risk difference; CI ¼ confidence interval; DELTA ¼ Drug Eluting Stent for Left Main Coronary Artery; HR ¼ hazard ratio; ST ¼ stent thrombosis; TLR ¼ target lesion revascularization; TVR ¼
target vessel revascularization; other abbreviations as in Table 1.
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FIGURE 2 Time-to-Event Curves
(A) Time-to-event curves for composite events of death, myocardial infarction (MI), or cerebrovascular accident (CVA) in DELTA 2 (Drug Eluting Stent for Left Main
Coronary Artery) versus DELTA 1 coronary artery bypass grafting (CABG) cohort. ARD ¼ absolute risk difference; HR ¼ hazard ratio. (B) Time-to-event curves for death,
MI, CVA, and target vessel revascularization (TVR) in DELTA 2 versus DELTA 1 CABG cohort.
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that this finding was due to selection bias, as femoral
access was chosen by the operators in more complex
procedures.
In DELTA 2, a 2-stent strategy was chosen by the
operators in a minority of cases (20.4%), reflecting the
current standard of care in bifurcation treatment (33).
Although several randomized clinical trials have
evaluated the optimal stenting strategy (34–39) in
non–left main coronary artery bifurcations, few data
are available about the optimal stenting strategy of
left main coronary artery bifurcations. Several
observational studies have suggested that a single-
stent strategy may be superior to a 2-stent strategy
also in the setting of left main coronary artery bifur-
cation, but these studies are naturally confounded by
selection bias. The ongoing EBC MAIN (European
Bifurcation Club Left Main) study is the first ran-
domized multicenter clinical trial so far comparing
true ULMCA bifurcation treatment with a planned
single- versus dual-stent strategy with respect to
death, TLR, and MI at 1 year (NCT02497014).
COMPARISON BETWEEN DELTA 2 AND HISTORICAL
DELTA 1 CABG PATIENTS. In the SYNTAX trial, elec-
tive PCI using first-generation DES for the left main
coronary artery had a similar occurrence of the primary
endpoint of MACCE compared with CABG in the subset
of patients with ULMCAdisease (22,23). Recently in the
EXCEL trial, PCI with new-generation DES showed
similar rates of the primary endpoint of death, MI, or
stroke at 3 years compared with CABG (24). However,
the rate of repeat revascularization was greater in the
PCI group (12.6% vs. 7.5%, p < 0.001).
Higher rates with PCI for the primary endpoint of
all-cause mortality, nonprocedural MI, any repeat
coronary revascularization, and stroke were reported
in the NOBLE trial (25). However, as recently
demonstrated by Capodanno et al. (40), there is an
important difference in the prognostic role between
repeat revascularization and the other components of
MACCE, such as death, MI, and stroke.
In the DELTA 2 registry, there was no parallel
contemporary CABG group. The surgical cohort of the
DELTA 1 population was therefore used in this study as
a historical surgical group and compared with
DELTA 2. Patients in the DELTA 2 cohort were older;
were more frequently male; more frequently had
hypertension, dyslipidemia, and histories of CABG and
PCI; and more often presented with non–ST-segment
elevation MI or ST-segment elevation MI. More
patients treated with CABG in DELTA 1 had higher
SYNTAX scores and elective procedure. Notably, in
the DELTA 1 CABG cohort, 187 patients (27.7%) had
complete arterial revascularization. In the EXCEL trial,
24.8% of patients in the CABG group had complete
arterial revascularization, not significantly different
from what was reported in SYNTAX and also in the
DELTA 1 CABG cohort and despite the protocol
recommendation to aim for complete arterial
revascularization.
A propensity score was generated by means of a
logistic regression model to adjust for differences in
the 2 study populations. Considering the difference
in follow-up duration (median 501 days in DELTA 2
and 1,524 days in DELTA 1 CABG), all endpoints were
compared at 501 days of follow-up. The occurrence of
the primary endpoint of death, MI, and CVA was
lower in the DELTA 2 PCI cohort compared with the
historical DELTA 1 CABG cohort. In particular, PCI
was associated with lower risk for cerebrovascular
events. Conversely, an advantage of CABG was
observed in terms of repeated coronary revasculari-
zation. Indeed, no difference was observed in
MACCE. Our results are comparable with those
reported from randomized trials, although our study
population was a real-world population including
patients who, because of clinical presentation,
comorbidities, or anatomic complexity, would have
been excluded from randomized controlled trials.
STUDY LIMITATIONS. First, given the observational,
retrospective design our findings precludes causal
inferences.
Second, because of the “all-comers” multicenter
design, there may have been differences among
centers in the strategy regarding patient selection for
PCI or CABG.
Third, comparisons between PCI with new-
generation DES and CABG are based on contempo-
rary and historical cohorts, respectively, with
different enrolling centers and patterns of practice.
As such, intercenter heterogeneity between cohorts
may be substantial, and more sophisticated methods
to account for intercenter heterogeneity, such as
multilevel hierarchical modeling, could not be
performed. We attempted to attenuate the effect of
intercenter heterogeneity by including trial identi-
fiers as a covariate within the propensity-stratified
Cox model.
Fourth, data were collected at each center within
the hospital network, and adjudication of the
outcomes was largely dependent on individual
institutions. Therefore we cannot exclude that in the
absence of site monitoring and a formal clinical
events committee adjudication underreporting of
MACCE may have occurred.
Fifth, despite the implementation of non-
parsimonious propensity score adjustment between
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revascularization strategies, our effect estimates are
subject to residual confounding bias. However, our
findings were consistent with randomized controlled
trial data in terms of magnitude and direction of the
effects on both primary and secondary outcomes.
Sixth, given the lack of standardized, prospective
data collection, our findings are also subject
to substantial intercenter variability and possibly
underestimation of the event rates.
Seventh, data on medication regimens and
adherence, which are known to influence long-term
outcomes after coronary revascularization, were not
available.
Finally, the follow-up time for comparisons
between the DELTA 2 PCI cohort and the DELTA 1
CABG cohort was relatively short (501 days); longer
clinical follow-up may abrogate the early advantage
observed with PCI.
CONCLUSIONS
In the large, international, multicenter all-comers
DELTA 2 registry, PCI with new-generation DES was
associated with acceptable rates of the composite
endpoint of death, MI, or CVA as well as the second-
ary endpoint of MACCE. The occurrence of the
primary endpoint of death, MI, or CVA was lower in
the PCI DELTA 2 group compared with the historical
DELTA 1 CABG cohort. An advantage of PCI was
observed with respect to CVA, while an advantage
of CABG was observed with respect to TVR and TLR
occurrence.
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